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Introduction A small but increasing number of patients with inﬂammatory bowel disease are diagnosed during childhood or
adolescence, and disease distribution and severity at onset vary according to the age at diagnosis. Clinical factors present at the
time of diagnosis can be predictive of the disease course.
Aim The aim of this study was to characterize disease behavior and the cumulative complications and extraintestinal
manifestations 10 years after the diagnosis and to assess their association with age at diagnosis.
Patients and methods Data of patients participating with the Swiss IBD cohort study registry, a disease duration of 10 years
and a complete data set were analyzed. The outcome was deﬁned as the cumulative change of disease behavior, the occurrence
of extra-intestinal manifestations or complications, and the necessity for medical or surgical interventions.
Results A total of 481 patients with Crohn’s disease (CD) and 386 patients with ulcerative colitis (UC), grouped according to
disease onset before 10, 17, 40, or after 40 years of age, were analyzed. Despite differences in sex, initial disease location, and
smoking habits, at 10 years after the diagnosis, no difference was found regarding disease behavior in CD or regarding
progression of disease extension in UC. Similarly, no age-of-onset-dependent cumulative need for medical or surgical therapies
was found. However, higher rates of anemia and lower rates of arthralgia and osteopenia were found in both pediatric-onset CD
and UC, and a tendency toward higher rates of stomatitis in pediatric-onset CD, and of primary sclerosing cholangitis and
ankylosing spondylitis in pediatric-onset UC.
Conclusion After 10 years of disease evolution, age at disease onset is not anymore associated with disease behavior but only
with a small difference in the occurrence of speciﬁc extraintestinal manifestations and complications. Eur J Gastroenterol Hepatol
30:598–607
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Introduction
Inﬂammatory bowel disease (IBD), which includes Crohn’s
disease (CD) and ulcerative colitis (UC) and indeterminate
colitis [IBD-unclassiﬁed (IBD-U)], is a group of chronic
inﬂammatory conditions affecting the gastrointestinal
(GI) tract. Intestinal manifestations, such as diarrhea,
abdominal pain, and bleeding, are the main symptoms, but
extraintestinal manifestations (EIMs) such as arthralgia,
or ocular, cutaneous, or hepatic disease also reveal active
inﬂammation. Furthermore, disease behaviour, including
disease expansion, and penetrating or stenosing behavior
is difﬁcult to predict.
An increasing number of patients with IBD are diag-
nosed during childhood and adolescence [1–4], even
though this number still represents a small percentage of
all patients with IBD. In contrast to adult disease onset,
there is a striking variety of pediatric-onset IBD char-
acteristics regarding disease distribution and severity at
onset, endoscopic appearance, histology, genetic back-
ground, comorbidities, complications during follow-up,
and response to or choice of various treatment options [5].
It even has been speculated that pediatric-onset CD is a
distinct disease entity, with probably different disease
subtypes [6].
In an effort to identify predicting factors for disease
evolution, numerous clinical follow-up studies have been
undertaken, and a North-South disease management gra-
dient across Europe [7], a change of disease location and
increase in EIMs over the years [8], and a controversial
dependency of disease evolution and incidence of compli-
cations on age at disease onset [8–14] have been reported.
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In a well-referenced study, Beaugerie et al. [15] reported
clinical factors that were present at the time of CD diagnosis
that were predictive of a disabling disease course over the
subsequent 5 years, including age less than 40 years and
perianal disease; disabling disease was deﬁned as steroid
dependency, hospitalization, and need for immunosup-
pression, resection, or perianal surgery. Other researchers
have identiﬁed ileal or ileocolonic disease, upper GI or
extensive small bowel involvement, stricturing behavior,
and deep colonic ulcerations as risk factors for a disabling
disease course [16–24]. In individuals with UC, a higher
education, female sex, and smoking were found to be risk
factors for ﬂare-ups during the ﬁrst 10 years [25]. It addi-
tionally has been reported that disease behavior during this
period is more aggressive in paediatric onset compared to
adult onset patients [26–28].
To date, no such data on patients with IBD are avail-
able in Switzerland. Therefore, in 2006, a nationwide
cohort study on patients with IBD, the SIBDC study, was
started [29], including a pediatric subcohort. The aim of
the present study was to characterize disease activity
10 years after diagnosis, with the primary question, whe-
ther 10 years after diagnose, disease behavior of patients
with pediatric onset would still differ from that of patients
with adult onset. For this purpose, we intended to analyze
the following variables: need for surgery, the prevalence of
EIMs and complications, the clinical situation, and therapy
requirements at 10 years of diagnosis. A further aim of the
study was to correlate disease activity with disease location
and behavior at diagnosis, for both pediatric-onset and
adult-onset IBD separately.
Patients and methods
Database
As of January 2017, 3582 patients diagnosed with CD,
UC, or IBD-U according to standard criteria [29] were
registered in the SIBDCS database. The study protocol for
this cohort study was approved by the central and local
ethics committees in Switzerland in 2006. Patient recruit-
ment since 2006 was conducted at six university centers in
Switzerland (Geneva, Lausanne, Bern, Basel, Zurich, and
St Gallen), as well as in select regional centers, with the
University of Lausanne serving as the coordinating center
and housing the database [30]. Retrospective data since
diagnosis were obtained from patient charts, and pro-
spective clinical data were collected during medical visits at
inclusion and follow-up visits by the patient’s gastro-
enterologist or a specialized study nurse who completed
clinical report forms. The forms were then sent to the data
center for validation and data entry.
Patients
From this registry, all patients with a disease duration of
10 years (108–132 months), inclusion to the registry at any
time after diagnosis, but participating actively 10 years after
diagnosis, were included in our study. The following data
were obtained from this database: date of birth, sex, family
history of IBD (ﬁrst degree relatives), age at IBD diagnosis
and at inclusion, type of IBD (CD, UC, or IBD-U), and
initial disease location (recorded according to Montreal
classiﬁcation) [31]. Furthermore, data on the occurrence of
strictures (duodenojejunal, ileal, ileocaecal valve, colon,
rectum and anus, and anastomosis, as diagnosed by endo-
scopic, radiologic, or surgical means), abdominal penetrat-
ing disease (enteroenteral, enterovesical, enterocutaneous
ﬁstulas and perforation, and intra-abdominal abscesses,
deﬁned as extraintestinal collections of ﬂuid, as diagnosed
by radiologic or surgical means), perianal disease (high and
low perianal, perineal, vaginal, and chronic or acute anal
ﬁssures, vaginal ﬁstulas, and perianal abscesses, as diag-
nosed by clinical, radiologic or surgical examination) in CD,
and progression or extension of disease in UC were
retrieved. In addition, data on the occurrence of EIMs
(arthralgia/arthritis, uveitis/episcleritis, pyoderma gang-
renosum or erythema nodosum, aphthous oral ulcers,
ankylosing spondylitis, and primary sclerosing cholangitis),
intestinal and other complications [colorectal cancer, colo-
nic dysplasia, intestinal lymphoma, osteopenia as measured
by dual-energy X-ray absorptiometry measurements
according to guidelines, anemia (not owing to drugs), deep
venous thrombosis or pulmonary embolism, gallstone or
nephrolithiasis, malabsorption syndrome, massive lower GI
hemorrhage, perforation, or peritonitis], the necessity of
treatments, such as tumor necrosis α inhibitors (anti-TNFα),
independent of success, failure, or cessation of adverse
effects, of immunomodulators, corticosteroids or mesala-
zine, and the necessity for abdominal resectional surgery
[small bowel, ileocaecal, or any type of colonic resection
(right, left, sigmoid resection, subtotal colectomy, or total
proctocolectomy)], or surgery for abscess drainage, ﬁstu-
lectomy, seton placement, ﬁbrin/glue instillation, and
mucosal sliding ﬂap were obtained. The outcome was
deﬁned as the cumulative change of disease behavior, the
occurrence of EIM or complications, or the need for med-
ical or surgical therapies. Data on BMI and weight came
from measurements taken by the study nurse at the enroll-
ment visit and at follow-up, using the wall stadiometer and
weight scales available at the various study centers. Weight
and BMI data of healthy controls (HC) (10 209 female and
8138 male patients; 17–90 years) were obtained from the
Federal Ofﬁce of Public Health survey of 2007 [32]. The
patients were grouped according to the Paris classiﬁcation
[33] into categories based on age at diagnosis (<10, <17,
<40, or >40 years of age). The outcome variables were
dichotomized into present or absent.
Statistical analysis
The distribution of continuous data was assessed using
normal-QQ-plots. Gaussian distributed data are presented
as the mean ± SD and range, and non-Gaussian distributed
data are presented as the median and interquartile range
(IQR). Differences in the distribution of continuous data
between two or more groups were assessed using Student’s
t-test or analysis of variance for Gaussian data, and using
the Wilcoxon–Mann–Whitney rank sum or independent-
samples Kruskal–Wallis test for non-Gaussian data.
Categorical data are presented as raw counts and relative
percentages, and 95% conﬁdence intervals were derived
using Pearson–Klopper exact method. Differences in
the distribution of categorical data between two or more
groups were assessed using the χ2-test or Fisher’s exact
test in cases of insufﬁcient sample size. Bonferroni’s cor-
rection was used for multiple testing. Multivariate linear
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regression analysis was used to assess associations between
ages at diagnosis, adjusted for sex, smoking, and initial
disease location and continuous outcome variables.
Multivariate logistic regression was used for dichotomous
outcome variables. For the purpose of the present study, a
P-value less than 0.05 was considered statistically sig-
niﬁcant. Statistical analyses were performed using SPSS
statistics 23.0 (IBM Corp., Armonk, New York, USA).
Results
After the exclusion of 26 patients with IBD-U, data of 481
patients with CD (235 male and 246 female patients) and
386 patients with UC (202 male and 184 female patients),
a disease duration of 10 years, and an available annual
follow-up during the time window of 108–132 months
after the diagnosis could be obtained for analysis.
Patients with Crohn’s disease
Initial disease location at diagnosis only differed between
pubertal and older than 40 years patients. No comparison
was possible for upper GI disease, because not enough
patients had assessment of the upper GI at diagnosis
(Table 1). Sex distribution concerning smokers and initial
location was even in all age groups. At diagnosis, none of
the <10-year-old, 11.1% of the <17-year-old, 52.8% of
the <40-year-old, and 44.6% of the >40-year-old patients
were smokers (< 10 vs. <40 years: P= 0.003, <10 vs.
>40 years: P=0.01, and > 17 years vs. > or <40 years:
P<0.001). Ten years later, 12.5% of the <10-year-old,
23.8% of the <17-year-old, 38.4% of the <40-year-old,
and 31.5% of the >40-year-old patients had started or
continued smoking (<10 vs. > or <40 years: P=NS, <17
vs. <40 years: P=0.03, <17 vs. > 40 years: P=NS) and
27.3% of the <40-year-old and 29.4% of the >40-year-
old smokers had stopped smoking.
Disease behavior at 10 years after diagnosis was similar
in all age groups, and the same was true for the occurrence
of intestinal complications such as stenosis and abdominal
or perianal ﬁstulae or abscesses (Table 1). A snapshot of
Crohn’s disease activity index and C-reactive protein
(CRP) values at 10 years after diagnosis yielded similar
results. In addition, the rate of medical therapies admi-
nistered during the 10 years of disease course was similar
in all age groups, as was a snapshot of the rate of ongoing
therapies at 10 years after diagnosis (Table 2).
Intestinal resectional surgery was less frequently per-
formed, and anti-TNFα therapy was used more frequently
in pediatric-onset patients, especially in those requiring
intestinal resectional surgery (Table 2).
Aphthous stomatitis and ankylosing spondylitis were
more frequently seen in those with disease onset at less than
10 years of age, but the difference was not signiﬁcant,
whereas arthralgia and osteopenia were more frequent in
adult-onset CD (Table 3). Because of the small patient
numbers in the pediatric age groups, none of the compar-
isons yielded signiﬁcant results. Furthermore, vascular
events, malabsorption syndrome, perforation, peritonitis, or
intestinal neoplasia were rare complications and excluded
from the analysis (Table 3). Patients with anti-TNFα therapy
and disease onset at less than 40 years, the only really large
patient group, had signiﬁcantly higher rates of arthralgia
(41/73 without TNFα and 108/96 with TNFα, P=0.01),
uveitis (6/108 without and 26/178 with TNFα, P=0.03),
apthous stomatitis (9/36 and 36/168, P=0.02), and anky-
losing spondylitis (3/11 and 20/184, P=0.02). Only for
anemia, in patients with disease onset at less than 17 years,
the requirement of TNFα, as a marker for more severe
disease yielded a difference (0/16 without TNFα vs. 14/33
with TNFα, P=0.01). When taking surgery as a marker of
Table 1. Patient’s characteristics at diagnosis and after 10 years of disease evolution in Crohn’s disease
Age group at diagnosis
<10 years (n=8)a <17 years (n=63)b <40 years (n=318)c >40 years (n=92)d P-value
Age at last follow-up [median (IQR)] (years) 17.0 (2) 24.0 (11) 34.0 (10) 60.0 (12) <0.001
Sex (male/female) 5/3 34/29 146/172 50/42 0.3
Initial disease location [n (%)]
Ileal 1 (12.5) 9 (14.3) 71 (22.3) 23 (25.0) <0.001
Colonic 1 (12.5) 10 (15.9) 69 (21.7) 33 (35.9) 0.046a,c*
Ileocolonic 4 (50.0) 38 (60.3) 156 (49.1) 31 (33.7) 0.006a,d*
Upper gastrointestinal only 1 (12.5) 0 3 (0.9) 0 0.003b,d*
NA 1 (12.5) 6 (9.5) 19 (6.0) 5 (5.4)
Additional upper gastrointestinal 0 6 (9.5) 12 (3.7) 2 (3.8)
Intestinal complications after 10 years [n (%, 95% CI)]
Stenosis 2 (25, 3–65) 25 (40, 28–53) 123 (39, 33–44) 39 (42, 32–53) 0.8
Abscess 1 (13, 0–53) 18 (29, 18–41) 75 (24, 19–29) 18 (20, 12–29) 0.5
Abdominal ﬁstula 2 (25, 3–65) 10 (16, 8–27) 46 (15, 11–19) 13 (14, 8–23) 0.9
Perianal ﬁstula 0 (0, 0–37) 11 (18, 9–29) 65 (20, 16–25) 17 (19, 11–28) 0.5
Disease behavior after 10 years [n (%)]
B1 5 (62.5) 32 (50.8) 178 (56.0) 49 (53.3) 0.9
B2 1 (12.5) 21 (33.3) 94 (29.6) 30 (32.6)
B3 2 (25.0) 10 (15.9) 46 (14.5) 13 (14.1)
B1p (%B1) 1 (20.5) 11 (34.4) 50 (28.1) 13 (26.5) 0.8
B2p (%B2) 0 11 (52.4) 33 (35.1) 5 (20.0) 0.051
B3p (%B3) 1 (50.0) 5 (50.0) 19 (41.3) 5 (38.5) 0.9
CDAI at 10 years [median (IQR)] (years) 6.0 (10) 20.0 (44) 31.0 (64) 26.0 (51) 0.07
CRP at 10 years [median (IQR)] (mg/l) 3.0 (6) 3.9 (10) 4.8 (6) 3.7 (7) 0.9
Disease behavior: B1= inﬂammatory, B2= stenosing, B3= penetrating.
CDAI, Crohn’s disease activity index; CI, conﬁdence interval; CRP, C-reactive protein; IQR, interquartile range; p, perianal.
*Bonferroni corrected.
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disease severity, no difference was found for the occurrence
of EIMs or complications.
After adjusting BMI (kg/m2) to that of the Swiss
population of the same age, the differences between age
groups corresponded to that observed in the normal
population (data not shown). Ten years after disease onset,
the median BMI Z-scores did not differ from that of
healthy coevals in the youngest-onset female group [med-
ian Z-BMI patients − 0.73 vs. HC − 0.1 (IQR=1.1),
P= 0.3] but was lower in male patients [median Z-BMI
patients − 0.88 vs. HC − 0.11 (IQR=1), P= 0.01]. In those
with pubertal disease onset, both male and female patients
had a lower BMI Z-score [female patients − 0.5 (IQR= 1)
vs. HC − 0.17 (IQR=1), P= 0.004, male patients − 0.15
(IQR= 1) vs. HC − 0.09 (IQR=1), P= 0.02]. Only female
patients who were older than 17 years at onset and
younger than 40 years after 10 years from diagnosis
[female patients, median Z-BMI − 0.49 (IQR= 1) vs. HC
− 0.17 (IQR= 1), P< 0.001; male patients − 0.1 (IQR=1)
vs. HC − 0.09 (IQR= 1), P=0.9] and male patients who
were older than 17 years at diagnosis and older than
40 years at 10 years from diagnosis [male patients − 0.27
(IQR= 0.9) vs. − 0.11 (IQR=1), P<0.001; female
patients − 0.28 (IQR= 0.8) vs. HC − 0.16 (IQR=1),
P=0.5] had lower Z-BMI than HC. In patients diagnosed
after the age of 40 years, Z-BMI did not differ or was
higher [female patients − 0.07 (IQR=1) vs. HC − 0.16
(IQR= 1), P=0.2, male patients=0.44 (IQR= 1) vs.
− 0.05 (IQR= 1), P<0.001] compared with that of HC.
The rate of ileocolonic disease location was correlated
with young age at diagnosis (R=0.11, P= 0.01), but not
anymore after 10 years. The rate of arthralgia (R= 0.14,
P=0.001) and the rate of nephrolithiasis (R= 0.12,
P=0.007) were positively correlated, and the rate of
Table 2. Cumulative surgical and medical therapies in Crohn’s disease
Age group at diagnosis
<10 years (n=8)a <17 years (n=63)b <40 years (n=318)c >40 years (n=92)d P-value
Surgical therapies ever used [n (%, 95% CI)]
Intestinal resectional surgery (including ostomy,
anastomosis, or plasty)
3 (38, 9–76) 13 (21, 11–33) 105 (33, 28–38) 38 (41, 31–52) 0.04b,d
Surgery for abdominal or perianal ﬁstula or abscesses 1 (13, 0–53) 17 (27, 17–40) 73 (23, 18–28) 20 (22, 14–32) 0.8
Any surgery 3 (38, 9–76) 25 (40, 28–53) 146 (46, 40–52) 45 (49, 38–60) 0.7
Medical therapies ever used [n (%, 95% CI)]
5-ASA 7 (88, 47–100) 35 (56, 42–68) 193 (61, 55–66) 51 (55, 45–66) 0.3
Systemic CS 8 (100, 63–100) 55 (87, 77–94) 282 (89, 85–92) 76 (83, 73–90) 0.3
Immunomodulators 7 (88, 47–100) 60 (95, 87–99) 284 (89, 85–93) 80 (87, 78–93) 0.4
Calcineurin inhibitors 0 (0, 0–37) 0 (0, 0–6) 9 (2.8, 1–5) 0 (0, 0–4) 0.3
TNFα inhibitors 7 (88, 47–100) 47 (75, 62–85) 204 (64, 59–69) 50 (54, 44–65) 0.06b,c,*
TNFα inhibitors and intestinal surgery 3 (100) 12 (92.3) 69 (65.7) 21 (55.3) 0.1b,d,*
TNFα inhibitors, no intestinal surgery 4/7 (57.1) 35/47 (74.5) 135/204 (66.2) 29/50 (58.0) 0.3
Medical therapies, snapspot at 10 years of follow-up [n (%, 95% CI)]
5-ASA 5 (63, 24–91) 16 (25, 15–38) 82 (26, 21–31) 20 (22, 14–32) 0.2a,b,*, 0.1a,
c,*
Systemic CS 6 (75, 35–97) 33 (52, 39–65) 153 (48, 43–54) 33 (36, 26–47) 0.2a,d,*, 0.2b,
d,*
Immunomodulators 4 (50, 16–84) 45 (71, 59–82) 190 (60, 54–65) 58 (63, 52–73) 0.3
Calcineurin inhibitors 0 (0, 0–37) 0 (0, 0–6) 3 (0.9, 0–3) 0 (0, 0–4) 1.0
TNFα inhibitors 6 (75, 35–97) 37 (59, 46–71) 179 (56, 51–62) 41 (45, 34–55) 0.1
Immunomodulators= azathioprine, purinethol, methotrexate; calcineurin inhibitors= cyclosporine, tacrolimus.
5-ASA, 5-aminosalicylic acid; CI, conﬁdence interval; CS, corticosteroids; TNFα, tumor necrosis factor α.
*Bonferroni corrected.
Table 3. Cumulative extraintestinal manifestations and complications in Crohn’s disease
Age group at diagnosis
<10 years (n=8)a <17 years (n=63)b <40 years (n=318)c >40 years (n=92)d P-value
Extraintestinal manifestations [n (%, 95% CI)]
Arthralgia 2 (25, 3–65) 19 (30, 19–43) 149 (47, 41–53) 51 (55, 45–66) 0.01
Uveitis 1 (13, 0–53) 5 (8, 3–18) 32 (10, 7–14) 10 (11, 5–19) 0.9
Pyoderma gangrenosum 0 (0, 0–37) 0 (0, 0–6) 4 (1, 0–3) 3 (3, 1–9) 0.4
Erythema nodosum 0 (0, 0–37) 6 (10, 4–20) 32 (10, 7–14) 3 (3, 1–9) 0.2
Aphtous oral ulcers 3 (38, 9–76) 9 (14, 7–25) 45 (14, 11–18) 9 (10, 5–18) 0.2
Ankylosing spondylitis 2 (25, 3–65) 1 (2, 0–9) 23 (7, 5–11) 9 (10, 5–18) 0.1a,b,*
Any extraintestinal manifestation 7 (88, 47–100) 30 (48, 35–61) 174 (55, 49–60) 55 (60, 49–70) 0.1
Complications [n (%, 95% CI)]
Osteopenia 0 (0, 0–37) 13 (21, 11–33) 50 (16, 12–20) 36 (39, 29–50) <0.001
Anemia (any, except owing to drug-related adverse events) 3 (38, 9–76) 14 (22, 13–34) 68 (21, 17–26) 21 (23, 15–33) 0.7
Thromboembolic events 0 (0, 0–37) 1 (2, 0–9) 7 (2, 1–4) 5 (5, 2–12) 0.7
Gallstone 0 (0, 0–37) 0 (0, 0–6) 11 (4, 2–6) 5 (5, 2–12) 0.3
Nephrolithiasis 0 (0, 0–37) 0 (0, 0–6) 4 (1, 0–3) 5 (5, 2–12) 0.1c,d,*
Massive hemorrhage 0 (0, 0–37) 4 (6, 2–15) 14 (4, 2–7) 6 (7, 2–14) 0.7
Any complication 3 (38, 9–76) 27 (43, 30–56) 131 (41, 36–47) 50 (44, 44–65) 0.2
CI, conﬁdence interval.
*Bonferroni corrected.
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growth impairment (R= − 0.195, P<0.001) was nega-
tively correlated with increasing age at diagnosis. The
younger the patient at diagnosis, the higher was the rate of
perianal disease (R= 0.92, P= 0.04), the lower was the
rate of resectional surgery (R=0.1, P= 0.14), and the
higher that of cumulative therapy with anti-TNFα anti-
bodies (R=0.13, P= 0.004).
The multivariate analysis showed that age at diagnosis,
corrected for sex, initial disease location, and smoking,
was associated with arthritis at any time, but not with any
other outcome variable (Table 4).
Ulcerative colitis patients
The rate of pancolonic disease location was signiﬁcantly
higher in patients with disease onset at less than 10 years
of age at diagnosis, and at 10 years after diagnosis, it was
high in both age groups, the <10 and the <17 years old
(Table 5). Sex distribution concerning smokers and initial
location was even in all age groups. At diagnosis, none of
the <10-year-old, 4% of the <17-year-old, 23.7% of the
<40-year-old, and 17.8% of the >40-year-old patients
were smoking (< 10 vs. <40 years: P=0.02, <10 vs.
>40 years: P= 0.053, <17 vs. <40 years: P= 0.02, <17 vs.
>40 years: P=NS). At 10 years after the diagnosis, none
of the <10-year-old, 16.0% of the <17-year-old, 13.8% of
the <40-year-old, and 11.1% of the >40-year-old patients
had started or continued smoking (all comparisons,
P=NS) and 41.7% of the <40-year-old and 37.5% of the
>40-year-old smokers had stopped smoking. At the last
follow-up, a snapshot of CRP values showed no difference
between age groups, but Modiﬁed Truelove Witts Activity
Index was lowest in the early-onset patients.
Intestinal resectional surgery has been carried out at
similar rates in all age groups. Except for immunomodu-
lators, which were most frequently used in those diagnosed
at younger than 10 years, all medical treatments were used
with similar frequency in all age groups (Table 6). Ten
years after diagnosis, overall EIMswere least frequent in
those with disease onset at less than 10 years of age.
Anemia occurred most frequently in pediatric-onset
patients (Table 7). Other complications, such as osteope-
nia, intestinal neoplasia, or gallstones and kidney stones
have not been reported in patients diagnosed before
10 years of age. Patients with surgical interventions with
disease onset at less than 17 years of age and less than
40 years of age had signiﬁcantly higher rates of osteopenia
(<17 years: 0/20 without and 3/2, P= 0.004 with surgery,
Table 5. Patient characteristics at diagnosis and after 10 years of disease evolution of ulcerative colitis
Age group at diagnosis
<10 years (n=18)a <17 years (n=25)b <40 years (n=253)c >40 years (n=90)d P-value
Age at last follow-up [median (IQR)] (years) 15.5 (4) 24.0 (3) 38.0 (11) 29.0 (12) <0.001
Sex (male/female) 6/12 15/10 125/128 56/34 0.06
Initial disease location [n (%)]
Pancolitis 13 (72.1) 14 (56.0) 91 (36.0) 34 (37.8) <0.05
Left sided 3 (16.7) 5 (20.0) 97 (38.3) 36 (40.0)
Proctitis 0 2 (8.0) 41 (16.2) 13 (14.4)
NA 2 (11.1) 4 (16.0) 24 (9.5) 7 (7.8)
Disease location after 10 years [n (%, 95% CI)]
Pancolitis 14 (77.8) 14 (56.0) 98 (38.7) 27 (30.0) 0.001, 0.1a,c,*, 0.03a,d,*
Left sided 2 (11.1) 4 (16.0) 104 (41.1) 45 (50.0)
Proctitis 1 (5.6) 6 (24.0) 49 (19.4) 15 (16.7)
NA 1 (5.6) 1 (4.0) 2 (0.9) 3 (3.3)
MTWAI at 10 years [median (IQR)] 0.0 (0) 2.0 (0) 2.0 (3) 2.0 (4) <0.001
CRP at 10 years [median (IQR)] (mg/l) 4.0 (4) 3.5 (2.5) 2.8 (4) 3.0 (4) 0.2
Disease location: 1= pancolitis, 2= left sided, 3= proctitis.
CI, conﬁdence interval; CRP, C-reactive protein; IQR, interquartile range; MTWAI, Modiﬁed Truelove Witts Activity Index.
*Bonferroni corrected.
Table 4. Association of age at diagnosis, initial disease location, sex, and smoking with outcome at 10 years in patients with Crohn’s disease
(multivariate analysisa)
EIM: stomatitis EIM: arthritis Intestinal surgery TNFα ever
Age group (years)
<10 2.74 (0.48–15.59); 0.3 0.76 (0.13–4.30); 0.76 1.11 (0.16–7.70); 0.92 0.57 (0.15–2.15); 0.41
<17 1 (ref) 1 (ref) 1 (ref) 1 (ref)
<40 0.89 (0.39–2.03); 0.78 2.04 (1.11–3.76); 0.02 1.00 (0.27–3.74); 0.99 0.88 (0.37–2.08); 0.77
>40 0.61 (0.22–1.71); 0.34 2.99 (1.47–6.08); 0.00 0.98 (0.24–4.07); 0.98 0.86 (0.34–2.17); 0.74
Female sex 1.37 (0.79–2.36); 0.26 1.50 (1.03–2.17); 0.04 0.47 (0.22–1.00); 0.05 0.86 (0.56–1.36); 0.55
Initial location
Not available 1.87 (0.57–6.14); 0.30 1.18 (0.51–2.73); 0.70 1.04 (0.32–3.37); 0.95 0.81 (0.37–1.75); 0.59
Ileal 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Clonic 1.83 (0.79–4.20); 0.16 1.22 (0.71–2.11); 0.47 0.84 (0.37–1.86); 0.66 0.97 (0.59–1.59); 0.90
Ileocolic 1.37 (0.64–2.94); 0.42 1.10 (0.68–1.77); 0.71 0.33 (0.07–1.49); 0.15 0.46 (0.22–0.96); 0.04
Upper gastrointestinal only NA 1.69 (0.21–13.48); 0.62 – –
Smoker at last visit 0.96 (0.49–1.90); 0.92 1.39 (0.57–2.23); 0.17 1.81 (0.59–5.56); 0.28 1.27 (0.63–2.56); 0.495
Smoker at diagnosis 1.14 (0.58–2.27); 0.70 0.84 (0.52–1.34); 0.46 0.27 (0.07–1.02); 0.05 0.71 (0.39–1.31); 0.274
EIM, extraintestinal manifestation; TNFα, tumor necrosis factor α.
aExpressed as odds ratio and 95% conﬁdence interval for binary, and as linear regression coefﬁcient and 95% conﬁdence interval for continuous variables.
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<40 years: 16/192 vs. 8/37, P= 0.048). Patients with anti-
TNFα therapy and disease onset at less than 40 years of
age, the only really large patient group, had signiﬁcantly
higher rates of arthralgia (50/126 without TNFα and
36/41 with TNFα, P= 0.01), osteopenia (61/147 without
and 25/20 with TNFα, P=0.002), or anemia stomatitis
(50/144 and 36/23, P< 0.001).
After adjustment with the Swiss population of the same
age, the differences in BMI between age groups corre-
sponded to the differences in the normal population (data
not shown). However, only patients diagnosed before the
age of 10 years had BMI Z-scores comparable to their
healthy age peers [female patients< 10 years, median
Z-BMI: 0.15 (IQR=1) vs. HC − 0.1 (IQR= 1.1), P= 0.8;
male patients<10 years, − 0.43 (IQR=2) vs. HC − 0.11
(IQR= 1), P=0.4]. In patients with disease onset at less
than 17 years of age, female but not male patients had a
lower mean Z-BMI than that of their healthy counterparts
[female patients, median Z-BMI − 0.73 (IQR= 1) vs. HC
− 0.17 (IQR= –), P=0.004; male patients 0.41 (IQR=4)
vs. HC − 0.09 (IQR=1), P= 0.14]. In patients diagnosed
at >17 and <40 years of age, both female and male
patients had the same BMI as HC [female patients − 0.35
(IQR= 1) vs. − 0.17 (1), P= 0.1; male patients − 0.13
(IQR= 1) vs. HC − 0.09 (IQR=1), P= 0.4] at 10 years
after diagnosis, but in those >17 years and >40 years of
age at diagnosis, female and male patients had a lower
BMI Z-score than their healthy counterparts [female
patients − 0.6 (IQR=1) vs. − 0.16 (IQR=1), P=0.002,
male patients 0.09 (IQR= 1) vs. HC − 0.11 (IQR=1),
P=0.02] at 10 years after diagnosis. In patients older than
40 years of age at diagnosis, the median Z-BMI was lower
in female patients [− 0.9 (IQR= 1) vs. HC − 0.16
(IQR= 1), P< 0.001] but not in male patients [ − 0.01
(IQR= 2) vs. − 0.05 (IQR=1), P=0.9].
Pancolitis at diagnosis (R=0.11, P=0.02, Kendall’s τb)
and after 10 years (R=0.11, P=0.02) was correlated with
younger age at diagnosis. The rate of arthralgia (R=0.15,
Table 6. Cumulative surgical and medical therapies in ulcerative colitis
Age group at diagnosis
<10 years (n=18)a <17 years (n=25)b <40 years (n=253)c >40 years (n=90)d P-value
Resectional surgery [n (%, 95% CI)] 2 (11, 1–35) 3 (12, 3–31) 22 (9, 6–13) 9 (10, 5–18) 0.9
Medical therapies ever used [n (%, 95% CI)]
5-ASA 16 (89, 65–99) 24 (96, 80–100) 241 (95, 92–98) 88 (98, 92–100) 0.4
Systemic CS 17 (94, 73–100) 21 (84, 64–95) 214 (85, 80–89) 76 (84, 75–91) 0.7
Immunomodulators 17 (94, 73–100) 20 (80, 59–93) 172 (68, 62–74) 65 (72, 62–81) 0.1a,c,*, 0.2a,d,*
Calcineurin inhibitors 2 (11, 1–35) 4 (16, 5–36) 33 (13, 9–18) 8 (9, 4–17) 0.7
TNFα inhibitors 5 (28, 10–53) 10 (40, 21–61) 86 (34, 28–40) 31 (34, 25–45) 0.9
Medical therapies at 10 years [n (%, 95% CI)]
5-ASA 14 (78, 52–94) 19 (76, 55–91) 188 (74, 68–80) 65 (72, 62–81) 0.9
Systemic CS 7 (39, 17–64) 11 (44, 24–65) 129 (51, 45–57) 35 (39, 29–50) 0.2
Imunomodulators 15 (83, 59–96) 18 (72, 51–88) 124 (49, 43–55) 42 (47, 36–57) 0.005, 0.2a,c,*, 0.04a,d,*
Calcineurin inhibitors 0 (0, 0–19) 1 (5, 0–20) 17 (7, 4–11) 4 (4, 1–11) 0.6
TNFα inhibitors 3 (17, 4–41) 7 (28, 12–49) 64 (25, 20–31) 24 (27, 18–37) 0.8
Imunomodulators= azathioprine, purinethol, methotrexate; calcineurin inhibitors= cyclosporine, tacrolimus.
5-ASA, 5-aminosalicylic acid; CI, conﬁdence interval; CS, corticosteroids; TNFα, tumor necrosis factor α.
*Bonferroni corrected.
Table 7. Cumulative extraintestinal manifestations and complications in ulcerative colitis
Age group at diagnosis
<10 years (n=18)a <17 years (n=25)b <40 years (n=253)c >40 years (n=90)d P-value
Extraintestinal manifestations [n (%, 95% CI)]
Arthralgia 1 (6, 0–27) 7 (28, 12–49) 77 (30, 25–37) 39 (43, 33–54) 0.009, 0.1a,d,*
Uveitis 0 (0, 0–19) 2 (8, 1–26) 16 (6, 4–10) 5 (6, 2–12) 0.7
Pyoderma gangrenosum 0 (0, 0–19) 1 (4, 0–20) 5 (2, 1–5) 1 (1, 0–6) 0.7
Erythema nodosum 0 (0, 0–19) 1 (4, 0–20) 10 (4, 2–7) 0 (0, 0–4) 0.2
Aphtous oral ulcers 2 (11, 1–35) 1 (4, 0–20) 16 (6, 4–10) 3 (3, 1–9) 0.5
Ankylosing spondylitis 0 (0, 0–19) 1 (4, 0–20) 11 (4, 2–8) 4 (4, 1–11) 0.8
PSC 0 (0, 0–19) 3 (12, 3–31) 5 (2, 1–5) 1 (1, 0–6) 0.02b,c,*, 0.06b,d,*
Any type of extraintestinal manifestation 3 (17, 4–41) 12 (48, 28–69) 96 (38, 32–44) 42 (47, 36–57) 0.2a,b,*, 0.1a,d,*
Complications [n (%, 95% CI)]
Osteopenia 0 (0, 0–19) 5 (20, 7–41) 45 (18, 13–23) 19 (21, 13–31) <0.001
Anemia (any, except owing to drug-related
adverse events)
10 (56, 31–78) 13 (52, 31–72) 59 (23, 18–29) 15 (17, 10–26) <0.001, 0.1a,c; a,d,*,
<0.001b,c; b,d,*
Thromboembolic events 0 (0, 0–19) 0 (0, 0–14) 10 (4, 2–6) 10 (11, 5–18) 0.06c,d,*
Gallstone 0 (0, 0–19) 0 (0, 0–14) 1 (0.4, 0–2) 7 (8, 3–15) <0.001
Nephrolithiasis 0 (0, 0–19) 0 (0, 0–14) 5 (2, 1–5) 4 (4, 1–11) 0.4
Massive hemorrhage 0 (0, 0–19) 3 (12, 3–31) 4 (2, 0–4) 1 (1, 0–6) 0.01b,c,*, 0.06b,d,*
Growth failure 8 (44, 9–58) 2 (8, –3–19) 0 (0, 0–1) 0 (0, 0–4) 0.048a,b; b,d,*,
<0.001a,c; a,d; b,c,*
Any complication 11 (61, 36–83) 12 (52, 28–69) 97 (38, 32–45) 41 (46, 35–56) 0.2
CI, conﬁdence interval; PSC, primary sclerosing cholangitis.
*Bonferroni corrected.
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P=0.002), the rate of thrombotic events (R=0.14, P=0.004),
and the presence of gallstones (R=0.19, P<0.001) were
positively correlated with increasing age at diagnosis, whereas
anemia was negatively (R=−0.19, P<0.001) correlated with
increasing age at diagnosis. No correlation was found with age
at diagnosis and the need for resectional intestinal surgery or
any medical therapy.
The multivariate analysis showed that age at diagnosis,
corrected for sex, initial disease location, and smoking,
was only associated with Modiﬁed Truelove Witts Activity
Index and CRP at the last follow-up, but not with any of
the other outcome variables (Table 8).
Discussion
Few studies have compared the disease evolution of var-
ious age groups over a period of 10 years. Two of these
studies, the report of the IBSEN registry and that of the
European collaborative study, collected data since 1990
[19,20]. Our registry included patients since 2006 and thus
describes the disease evolution of a different period.
Within the ﬁrst 10 years of the disease course of our
patients with CD, intestinal complications, such as ste-
nosing, penetrating disease, or perianal disease, occurred
at a similar cumulative rate in all age groups, and disease
behavior at 10 years was similar in all age groups.
Differences in initial disease locations, smoking habits at
diagnosis, or during the 10 years, as shown in our study,
and a higher prevalence in B2 and B3 disease behavior or
perianal disease at adult disease onset, as shown by others
[20,24,34–37], did not result in an age-of-onset dependent
rate of intestinal complications after 10 years of disease.
Parallelly, no age of onset dependent differences for the
rate of TNFα-antibody treatments, despite the increased
use in our patients with pediatric-onset CD in comparison
to earlier studies [38], or for the rate of surgical interven-
tions were found and our rates were comparable with rates
reported by others [5,39].
A similar picture emerged in our patients with UC;
disease location, with the same initial age-group dependent
distribution as already described by many groups [6,40],
had not changed after 10 years. Still, the rate of surgical
interventions was similar in all age groups, though lower
than in other recent reports [40], and except for
immunomodulators, medical therapies were used at a
similar rate in all age groups and similar to rates reported
by others [40].
We also looked at BMI Z-scores after 10 years and
found a possible age of onset-dependent difference in
patients with CD but not in those with UC. We could,
however, not compare and conﬁrm these ﬁndings with
results of other larger cohorts [41,42]. Lastly, the overall
frequency of EIMs or extraintestinal complications was
similar in all age groups of patients with CD and those
with UC, and to those of earlier reports [40,43–46].
We, however, found single age-dependent differences in
the frequency of EIMs or complications. In both disorders,
CD and UC, the rate of arthralgia and osteopenia was
lower and that of anemia higher in pediatric-onset
patients. Yet, the three disorders also affect the general
population in an age-dependent manner. For example:
peripheral joint pain and swelling have been reported in
14% of the general Italian adult [47], but not in the gen-
eral pediatric population. Regarding bone loss, this is a
process known to be associated with aging [48].
Moreover, bone mineral density is not routinely assessed
in children and in patients with pediatric-onset IBD.
Regarding the prevalence of anemia, especially iron-
deﬁciency anemia is known to be more frequent in the
general pediatric population [49,50]. Lastly, regarding
gallstone disease, nephrolithiasis, and thromboembolic
events, which are disorders with a higher prevalence in
IBD than in the background population, their increasing
incidence with older age in several countries has repeatedly
been reported, and the prevalence in our cohort did not
exceed that of the background population [51–53].
Therefore, the age-dependent rates of arthralgia, osteope-
nia, anemia, lithiases, and thromboembolic disease may at
least partly reﬂect more a general than a disease-speciﬁc
phenomenon.
Only the tendency toward an age-dependent distribu-
tion of aphthous stomatitis, with a high prevalence not
only in our youngest-onset patients but also in other
pediatric IBD cohorts [54], can be interpreted as disease
speciﬁc. Effectively, the prevalence of aphthous stomatitis
in the general population is similar in all age classes [55].
However, this result requires conﬁrmation by analyses of
larger cohorts.
Table 8. Association of age at diagnosis, initial disease location, sex, and smoking with outcome at 10 years in patients with ulcerative colitis
(multivariate analysisa)
Arthralgia Anemia Immunomodulators ever MTWAI at last follow-up CRP at last follow-up
Age group (years)
<10 0.14 (0.01–1.24); 0.08 0.72 (0.20–2.60); 0.62 3.52 (0.37–33.79); 0.28 −2.28 (−4.05 to −0.51); 0.01 8.33 (0.10–16.57); 0.05
<17 1 (ref) 1 (ref) 1 (ref) 0 (ref) 0 (ref)
<40 1.03 (0.40–2.62); 0.95 0.26 (0.11–0.63); 0.003 0.68 (0.24–1.94); 0.47 0.08 (−1.11–1.27); 0.90 −1.48 (−7.40–4.44); 0.62
>40 1.91 (0.71–5.13); 0.20 0.19 (0.07–0.51); 0.01 0.80 (0.26–2.46); 0.70 0.29 (−0.99–1.57); 0.66 0.01 (−6.47–6.49); 0.99
Female sex 1.54 (0.98–2.42); 0.06 2.81 (1.67–4.71); <0.001 0.97 (0.61–1.56); 0.91 −0.11 (−0.69–0.48); 0.73 0.32 (−2.70–3.34); 0.84
Initial location
Not available 0.81 (0.35–1.85); 0.61 0.89 (0.38–2.07); 0.79 1.28 (0.51–3.23); 0.60 −0.06 (−1.12–1.00); 0.92 2.58 (−2.44–7.61); 0.31
Pancolitis 1 (ref) 1 (ref) 1 (ref) 0 (ref) 0 (ref)
Left sided 1.17 (0.70–1.96); 0.54 0.76 (0.43–1.35); 0.34 0.78 (0.45–1.35); 0.37 −0.30 (−0.97–0.38); 0.39 1.73 (−1.78–5.24); 0.33
Proctitis 1.06 (0.54–2.08); 0.88 0.40 (0.17–0.95); 0.04 0.23 (0.12–0.45); <0.001 −0.39 (1.38–0.40); 0.28 0.99 (−3.72–5.70); 0.68
Smoker at last visit 1.13 (0.55–2.29); 0.74 0.54 (0.22–1.36); 0.19 0.82 (0.40–1.71); 0.60 1.12 (0.18–2.07); 0.02 1.52 (−3.02–6.06); 0.51
Smoker at diagnosis 1.00 (0.54–1.82); 0.99 0.88 (0.43–1.81); 0.73 0.71 (0.39–1.30); 0.26 0.17 (−0.63–0.96); 0.68 −2.44 (−6.45–1.57); 0.23
CRP, C-reactive protein; MTWAI, Modiﬁed Truelove Witts Activity Index.
aExpressed as odds ratio and 95% conﬁdence interval for binary, and as linear regression coefﬁcient and 95% conﬁdence interval for continuous variables.
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Our ﬁndings are in contradiction with those of earlier
reports. For instance, intestinal resectional interventions
have been reported to be less frequently done in pediatric-
onset patients, although, if done, these are carried out
earlier during the disease course [56–58]. It must, however,
be emphasized that the analyses of these latter studies have
been done in patients with various disease durations. Our
study is the ﬁrst to compare rates of disease manifestations
in patients with IBD of different age groups after a ﬁxed
period of time, and this cumulative view zooms off many
of the differences.
The present study has several limitations: First, this
study is not population based. In Switzerland, many adult
patients with IBD are followed by gastroenterologists in
private practice, particularly patients with uncomplicated
diseases living in regions without easy access to university
hospitals. Second, inclusion of patients to our registry
occurred at different times after diagnosis, with variable
durations of prospective follow-ups. Therefore, the
chronology of the events, and their temporal relation could
not be analyzed. Third, our pediatric groups were of small
size and required the use of nonparametric tests leading to
lower statistical power. Pooling of pediatric data from
more registries would offer better insight into the chron-
ology of disease-related events.
In summary, up to 10 years of follow-up, the course of
the intestinal disease was not dependent on the age of
onset of CD or UC. EIMs and complications seem to be
age dependent. Arthralgia and osteopenia occur more
often in adult-onset patients, whereas anemia and aph-
thous stomatitis are more frequent in the pediatric-onset
patient.
Acknowledgements
The authors thank all the patients for their collaboration
and the members of the Swiss Inﬂammatory Bowel Disease
Cohort Study for their contribution.
Members of the Swiss IBD Cohort Study Group:
Claudia Anderegg; Peter Bauerfeind; Christoph Beglinger;
Stefan Begré; Dominique Belli; José Bengoa; Luc
Biedermann; Janek Binek; Mirjam Blattmann; Nadia
Blickenstorfer; Stephan Boehm; Jan Borovicka; Christian
Braegger; Patrick Bühr; Bernard Burnand; Emmanuel
Burri; Sophie Buyse; Matthias Cremer; Dominique Criblez;
Philippe de Saussure; Lukas Degen; Joakim Delarive;
Christopher Dörig; Barbara Dora; Gian Dorta; Tobias
Ehmann; Ali El Wafa; Mara Egger; Matthias Engelmann;
Christian Felley; Markus Fliegner; Nicolas Fournier;
Montserrat Fraga; Alain Frei; Pascal Frei; Remus Frei;
Michael Fried; Florian Froehlich; Raoul Furlano; Suzanne
Gallot-Lavallée; Martin Geyer; Marc Girardin; Delphine
Golay; Tanja Grandinetti; Beat Gysi; Horst Haack;
Johannes Haarer; Beat Helbling; Peter Hengstler;
Denise Herzog; Cyrill Hess; Klaas Heyland; Thomas
Hinterleitner; Philippe Hiroz; Claudia Hirschi; Petr Hruz;
Pascal Juillerat; Rosmarie Junker; Christina Knellwolf;
Christoph Knoblauch; Henrik Köhler; Rebekka Koller;
Claudia Krieger; Gerd A. Kullak-Ublick; Markus Landolt;
Frank Lehmann; Valérie McLin; Philippe Maerten; Michel
Maillard; Christine Manser; Andrew Macpherson;
Michael Manz; George Marx; Rémy Meier; Christa
Meyenberger; Jonathan Meyer; Pierre Michetti; Benjamin
Misselwitz; Darius Moradpour; Patrick Mosler; Christian
Mottet; Christoph Müller; Pascal Müller; Beat Müllhaupt;
Claudia Münger; Leilla Musso; Andreas Nagy; Cristina
Nichita; Jan Niess; Natacha Noël; Andreas Nydegger;
Maliza Nzabonimpa; Nicole Obialo; Carl Oneta;
Cassandra Oropesa; Céline Parzanese; Laetitia-Marie
Petit; Franziska Piccoli; Julia Pilz; Gaëlle Pittet; Valérie
Pittet; Bruno Raffa; Ronald Rentsch; Sophie Restellini,
Jean-Pierre Richterich; Silvia Rihs; Jocelyn Roduit; Daniela
Rogler; Gerhard Rogler; Jean-Benoît Rossel; Markus
Sagmeister; Gaby Saner; Bernhard Sauter; Mikael
Sawatzki; Michael Scharl; Sylvie Scharl; Nora Schaub;
Martin Schelling; Susanne Schibli; Hugo Schlauri; Daniela
Schmid; Sybille Schmid; Jean-François Schnegg; Alain
Schoepfer; Christiane Sokollik; Frank Seibold; Gian-
Marco Semadeni; Mariam Seiraﬁ; David Semela; Arne
Senning; Marc Sidler; Johannes Spalinger; Holger
Spangenberger; Philippe Stadler; Volker Stenz; Michael
Steuerwald; Alex Straumann; Michael Sulz; Alexandra
Suter; Michela Tempia-Caliera; Joël Thorens; Sarah
Tiedemann; Radu Tutuian; Ueli Peter; Stephan Vavricka;
Francesco Viani; Roland Von Känel; Alain Vonlaufen;
Dominique Vouillamoz; Rachel Vulliamy; Helene Werner;
Paul Wiesel; Reiner Wiest; Tina Wylie; Jonas Zeitz;
Dorothee Zimmermann.
D.H., N.F., and C.B. were responsible for study plan-
ning, data analysis, and writing of the manuscript; D.H.,
C.B., P.B., V.R., R.K., K.H., A.N., J.S., S.S., and L.M.P.
carried out data collection and transfer to the registry. All
authors read and approved the ﬁnal manuscript.
The study was supported by a research grant from the
Swiss National Science Foundation (SIBDCS grant
no. 3347CO-108792).
Conﬂicts of interest
There are no conﬂicts of interest.
References
1 Lapidus A. Crohn’s disease in Stockholm County during 1990–2001:
an epidemiological update. World J Gastroenterol 2006; 12:75–81.
2 Loftus CG, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ,
Melton LJ 3rd, et al. Update on the incidence and prevalence of Crohn’s
disease and ulcerative colitis in Olmsted County, Minnesota,
1940–2000. Inﬂamm Bowel Dis 2007; 13:254–261.
3 Gunesh S, Thomas GA, Williams GT, Roberts A, Hawthorne AB. The
incidence of Crohn’s disease in Cardiff over the last 75 years: an update
for 1996–2005. Aliment Pharmacol Ther 2008; 27:211–219.
4 Chouraki V, Savoye G, Dauchet L, Vernier-Massouille G, Dupas JL,
Merle V, et al. The changing pattern of Crohn’s disease incidence in
northern France: a continuing increase in the 10- to 19-year-old age
bracket (1988–2007). Aliment Pharmacol Ther 2011; 33:1133–1142.
5 Frolkis AD, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, et al.
Risk of surgery for inﬂammatory bowel diseases has decreased over
time: a systematic review and meta-analysis of population-based stu-
dies. Gastroenterology 2013; 145:996–1006.
6 Van Limbergen J, Russel R, Drummond H, Aldhous M, Round N,
Nimmo E, et al. Deﬁnition of phenotype characteristics of
childhood-onset inﬂammatory bowel disease. Gastroenterology 2008;
135:1114–1122.
7 Wolters F, Joling C, Russel M, Sijbrandij J, de Bruin M, Odes S, et al.
Treatment inferred disease severity in Crohn’s disease: evidence for a
European gradient of disease course. Scand J Gastroenterol 2007;
42:333–344.
8 Abraham B, Mehta S, El-Serag H. Natural history of pediatric-onset
inﬂammatory bowel disease. A systematic review. J Clin Gastroenterol
2012; 46:581–589.
Age-dependent features of IBD after 10 years Herzog et al. www.eurojgh.com 605
Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
9 Freeman H. Comparison of longstanding pediatric-onset and adult-
onset Crohn’s disease. J Pediatr Gastroenterol Nutr 2004; 39:183–186.
10 Langholz E, Munkholm P, Krasilnikoff PA, Binder V. Inﬂammatory bowel
diseases with onset in childhood. Clinical features, morbidity, and
mortality in a regional cohort. Scand J Gastroenterol 1997; 32:139–147.
11 Mamula P, Markowitz JE, Baldassano RN. Inﬂammatory bowel disease
in early childhood and adolescence: special considerations.
Gastroenterol Clin North Am 2003; 32:967–995.
12 Sauer CG, Kugathasan S. Pediatric inﬂammatory bowel disease: high-
lighting pediatric differences in IBD. Gastroenterol Clin North Am 2009;
38:611–628.
13 Avinash B, Dutta AK, Chacko A. Pediatric inﬂammatory bowel disease in
South India. Indian Pediatr 2009; 46:639–640.
14 Law S, Li K. Age-related differences in the clinical course of Crohn’s
disease in an Asian population: a retrospective cohort review. Indian
Pediatr 2013; 50:1148–1152.
15 Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J.
Predictors of Crohn’s disease. Gastroenterology 2006; 130:650–656.
16 Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical
features and natural history of Crohn’s disease. Gastroenterology 1979;
77:898–906.
17 Bernell O, Lapidus A, Hellers G. Risk factors for surgery and post-
operative recurrence in Crohn’s disease. Ann Surg 2000; 231:38–45.
18 Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term
outcome of patients with active Crohn’s disease exhibiting extensive
and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;
97:947–953.
19 Wolters F, Russel M, Sijbrandij J, Schouten LJ, Odes S, Riis L, et al.
Disease outcome of inﬂammatory bowel disease patients: general
outline of a Europe-wide population based 10-year clinical follow-
up study. Scand J Gastroenterol Suppl 2006; 243:46–54.
20 Solberg I, Vatn M, Hoie O, Stray N, Sauar J, Jahnsen J, et al. Clinical
course in Crohn’s disease: results of a Norwegian population-based
ten-year follow-up study. Clin Gastroenterol Hepatol 2007;
5:1430–1438.
21 Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease.
Scand J Gastroenterol 2008; 43:948–954.
22 Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease
predicts changes in Crohn’s disease phenotype-results of a population-
based study of inﬂammatory bowel disease phenotype. Am J
Gastroenterol 2008; 103:3082–3093.
23 Romberg-Camps M, Dagnelie P, Kester A, Hesselink-van de Kruijs M,
Cilissen M, Engels L, et al. Inﬂuence of phenotype at diagnosis and of
other potential prognostic factors on the course of inﬂammatory bowel
disease. Am J Gastroenterol 2009; 104:371–383.
24 Thia K, Sandborn W, Harmsen W, Zinsmeister A, Loftus E. Risk factors
associated with progression to intestinal complications of Crohn’s
disease in a population-based cohort. Gastroenterology 2010;
139:1147–1155.
25 Höie O, Wolters F, Aamodt G, Solbergg C, Bernklev T, Odes S, et al.
Ulcerative colitis: Patient characteristics may predict 10-yr disease
recurrence in a Europe-wide population based cohort. Am J
Gastroenterol 2007; 102:1692–1701.
26 Solberg I, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al.
Clinical course during the ﬁrst 10 years of ulcerative colitis: results from a
population-based inception cohort (IBSEN Study). Scand J
Gastroenterol 2009; 44:431–440.
27 Lee J, Cheon J, Moon C, Park J, Hong S, Kim T, et al. Do patients with
ulcerative colitis diagnosed at a young age have more severe disease
activity than patients diagnosed when older? Digestion 2010;
81:237–243.
28 Gower-Rousseau C, Dauchet L, Vernier-Massouille G, Tilloy E, Brazier F,
Merle V, et al. The natural history of pediatric ulcerative colitis: a population-
based cohort study. Am J Gastroenterol 2009; 104:2080–2088.
29 Lennard-Jones JE. Classiﬁcation of inﬂammatory bowel disease. Scand
J Gastroenterol Suppl 1989; 170:2–6.
30 Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Betal B. Cohort
proﬁle: the Swiss Inﬂammatory Bowel Disease Cohort Study (SIBDCS).
Int J Epidemiol 2009; 38:922–931.
31 Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR,
et al. Toward an integrated clinical, molecular and serological classiﬁ-
cation of inﬂammatory bowel disease: Report of a Working Party of the
2005 Montreal World Congress of Gastroenterology. Can J
Gastroenterol 2005; 19:5–36.
32 Federal Ofﬁce of Public Health .Swiss Health Survey; 2007. Available at:
http://www.bfs.admin.ch/bfs/portal/de/index/dienstleistungen/pub
likationen_statistik/publikationskatalog.html?publicationID=3502.
[Accessed 11 December 2008].
33 Levine A, Grifﬁths A, Markowitz J, Wilson D, Turner D, Russell R, et al.
Pediatric modiﬁcation of the Montreal classiﬁcation for inﬂammatory
bowel disease: the Paris classiﬁcation. Inﬂamm Bowel Dis 2011;
17:1314–1321.
34 Kugathasan S, Densan L, Walters T, Kim M, Marigorta M, Schirmer M,
et al. Prediction of complicated disease course for children newly
diagnosed with Crohn’s disease: a multicenter inception cohort study.
Lancet 2017; 389:1710–1718.
35 Adler J, Dong S, Eder SJ, Dombkowski KJ. Perianal Crohn’s disease in
a large multicenter pediatric collaborative. J Pediatr Gastroenterol Nutr
2017; 64:e117–e124.
36 Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R,
Harmsen WS, Zinsmeister AR, et al. The natural history of ﬁstulizing
Crohn’s disease in Olmsted County, Minnesota. Gastroenterology
2002; 122:875–880.
37 Lovasz BD, Lakatos L, Horvath A, Szita I, Pandur T, Mandel M, et al.
Evolution of disease phenotype in adult and pediatric onset Crohn’s
disease in a population-based cohort. World J Gastroenterol 2013;
19:2217–2226.
38 Combé V, Salleron J, Savoye G, Dupas JL, Vernier-Massouille G,
Lerebours E, et al. Long-term outcome of treatment with inﬂiximab in
pediatric-onset Crohn’s disease: a population based study. Inﬂamm
Bowel Dis 2011; 17:2144–2152.
39 Burke JP, Vellupillai Y, O’Connell PR, Coffey JC. National trends in
intestinal resection for Crohn’s disease in the post-biologic aera. Int J
colorectal Dis 2013; 28:1401–1406.
40 Fumery M, Duricova D, Gower-Rousseau C, Annese V, Peyrin-
Biroulet L, Lakatos PL. Review article: the natural history of
paediatric-onset ulcerative colitis in population based studies. Aliment
Pharmacol Ther 2016; 43:346–355.
41 Duricova D, Fumery M, Annese V, Lakatos PL, Peyrin-Biroulet L,
Gower-Rousseau C. The natural history of Crohn’s disease in children:
a review of population based studies. Eur J Gastroenterol Hepatol 2017;
29:125–134.
42 Herzog D, Fournier N, Buehr P, Koller R, Rueger V, Heyland K,
Nydegger A, Spalinger J, Schibli S, Braegger C. Early-onset Crohn’s
disease is a risk factor for smaller ﬁnal height. Eur J Gastroenterol
Hepatol 2014; 26:1234–1239.
43 Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J,
et al. Extraintestinal minifestations of pediatric inﬂammatory bowel dis-
ease: prevalence, presentation and ant-TNF treatment. J Pediatr
Gastroenterol Nutr 2017; 65:200–206.
44 Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL,
Mouterde O, et al. Natural history of pediatric Crohn’s
disease: a population-based cohort study. Gastroenterology 2008;
135:1106–1113.
45 Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz-Vavricka M,
Navarini AA, et al. Chronological order of appearance of extraintestinal
manifestations relative to the time of IBD diagnosis in the Swiss
Inﬂammatory Bowel Disease Cohort. Inﬂamm Bowel Dis 2015; 21:
1794–1800.
46 Dotson J, Hyams J, Markowitz J, LeLeiko N, Mack D, Evans J, et al.
Extraintestinal manifestations of pediatric inﬂammatory bowel disease
and their relation to disease type and severity. J Pediatr Gastroenterol
Nutr 2010; 51:140–145.
47 Cimmino MA, Parisi M, Moggiana GL, Maio T, Mela GS. Prevalence of
self-reported peripheral joint pain and swelling in an Italian population:
the Chiavari Study. Clin Exp Rheumatol 2001; 19:35–40.
48 Cvijetić S, Korsić M. Apparent bone mineral density estimated from DXA
in healthy men and women. Osteoporos Int 2004; 15:295–300.
49 Goodhand J, Kamperidis N, Rao A, Laskaratos F, McDermott A,
Wahed M, et al. Prevalence and Management of anemia in children,
adolescents, and adults with inﬂammatory bowel disease. Inﬂamm
Bowel Dis 2012; 18:513–519.
50 Uijtershout L, Vloemans J, Vos R, Teunisse P, Hudig C, Bubbers S,
et al. Prevalence and risk factors of iron deﬁciency in healthy young
children of the southwestern Netherlands. J Pediatr Gastroenterol Nutr
2014; 58:193–198.
51 Jorgensen T. Gallstones. In: Talley N, Loke R III, Saito Y, editors. GI
epidemiology. Malden, MA: Blackwell Publishing; 2007. pp. 215–220.
52 Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology
of venous thromboembolism: similarities with atherothrombosis
and the role of inﬂammation. Thromb Haemost 2015;
113:1176–1183.
606 European Journal of Gastroenterology & Hepatology June 2018 •Volume 30 •Number 6
Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
53 Shoag J, Tasian GE, Goldfarb DS, Eisner BH. The new epidemiology of
nephrolithiasis. Adv Chronic Kidney Dis 2015; 22:273–278.
54 Hyman MB. Development of extra-intestinal manifestations in pediatric
patients with inﬂammatory bowel disease. Inﬂamm Bowel Dis 2009;
15:63–68.
55 Majorana A, Bardellini E, Flocchini P, Amadori F, Conti G, Campus G. Oral
mucosal lesions in children from 0 to 12 years old: ten years’ experience.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:e13–e18.
56 Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, et al.
Penetrating or stricturing diseases are the major determinants of time to
ﬁrst and repeat resection surgery in Crohn’s disease. Digestion 2013;
87:212–221.
57 Manser CN, Frei P, Grandinetti T, Biedermann L, Mwinyi J, Vavricka SR,
et al. Risk factors for repetitive ileocolic resection in patients with
Crohn’s disease: results of an observational cohort study. Inﬂamm
Bowel Dis 2014; 20:1548–1554.
58 Herzog D, Fournier N, Buehr P, Rueger V, Koller R, Heyland K, et al.
Prevalence of intestinal complications in inﬂammatory bowel disease:
a comparison between paediatric-onset and adult-onset patients. Eur J
Gastroenterol Hepatol 2017; 29:926–931.
Age-dependent features of IBD after 10 years Herzog et al. www.eurojgh.com 607
Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
